<DOC>
	<DOC>NCT02094703</DOC>
	<brief_summary>The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg) for short-term treatment to reduce symptoms in patients with symptomatic non complicated urinary tract infection in females.</brief_summary>
	<brief_title>The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>females (1865 years old) dysuria in symptomatic non complicated urinary tract infection Pediatric Patients (&lt; 18 years old) geriatric Patients (&gt; 65 years old) pregnant Patients Patients with complicated urinary tract infection sexually transmitted infections Patients with pathological abnormalities in the urinary bladder, including stone/mass Cathetermounted Neurological diseases/disorders patients with allergy/hypersensitivity with Levofloxacin/Solifenacin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>female</keyword>
	<keyword>age 18-65 years</keyword>
	<keyword>storage symptoms</keyword>
	<keyword>clinical urinary tract infection</keyword>
	<keyword>non complicated</keyword>
</DOC>